<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLOZAPINE <img border="0" src="../images/pr.gif"/></span><br/>(clo'za-pin)<br/><span class="topboxtradename">Clozaril, </span><span class="topboxtradename">Fazaclo<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antipsychotic</span>; <span class="classification">atypical</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 100 mg tablets and orally disintegrating tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Mechanism is not defined. Interferes with binding of dopamine to D<sub>1</sub> and D<sub>2</sub> receptors in the limbic region of brain. It binds primarily to nondopaminergic sites (e.g., alpha-adrenergic, serotonergic,
         and cholinergic receptors).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Utilized for treatment of schizophrenia uncontrolled by other agents.</p>
<h1><a name="uses">Uses</a></h1>
<p>Indicated only in the management of severely ill schizophrenic patients who have failed to respond to other neuroleptic agents.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Schizo-affective disorder, severe obsessive-compulsive disorder, bipolar disorder, dementia-related behavioral disorders.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe CNS depression, blood dyscrasia, history of bone marrow depression; patients with myeloproliferative disorders, uncontrolled
         epilepsy; clozapine-induced agranulocytosis, severe granulocytosis, chemotherapy, coma, leukemia, leukopenia, neutropenia,
         myocarditis, concurrent administration of benzodiazepines or other psychotropic drugs; renal failure, dialysis, hepatitis,
         jaundice; infants, lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Arrhythmias, GI disorders, narrow-angle glaucoma, hepatic and renal impairment, prostatic hypertrophy, history of seizures;
         patients with cardiovascular and/or pulmonary disease; cerebrovascular disease, cardiac arrhythmias, tachycardia, dehydration,
         neurological disease, tardive dyskinesia, previous history of agranulocytosis; surgery, glaucoma, infection, pregnancy (category
         B); older adults. Safety and efficacy in children have not been established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Schizophrenia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span>
<i>&gt;16 y:</i> Initiate at 2550 mg/d and titrate to a target dose of 350450 mg/d in 3 divided doses at 2 wk intervals, further
               increases can be made if necessary, max of 900 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Drug is usually withdrawn gradually over 12 wk if therapy must be discontinued.</li>
<li>Store the drug away from heat or light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Orthostatic hypotension, <span class="speceff-common">tachycardia,</span> ECG changes, increased risk of myocarditis especially during first month of therapy, pericarditis, pericardial effusion,
      cardiomyopathy, heart failure, MI, mitral insufficiency. <span class="typehead">GI:</span> Nausea, dry mouth, constipation, hypersalivation. <span class="typehead">Hematologic :</span>
<span class="speceff-life">Agranulocytosis</span>. <span class="typehead"> CNS:</span>  Seizures, <span class="speceff-common">transient fever,</span> sedation, <span class="speceff-life">neuroleptic malignant syndrome (rare)</span>, dystonic reactions (rare). <span class="typehead">Metabolic:</span> Hyperglycemia, diabetes mellitus. <span class="typehead">Urogenital:</span> Urinary retention.  <span class="typehead">Other:</span>
<span class="speceff-life">Increased mortality from severe hematologic, cardiovascular, and respiratory adverse effects.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> compound depressant effects; <span class="classification">anticholinergic agents</span> potentiate anticholinergic effects; <span class="classification">antihypertensive agents</span> may potentiate hypotension.  <span class="typehead">Herbal:</span>
<b>St. John's wort</b> and <b>kava</b> may increase sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 24 wk. <span class="typehead">Peak:</span> 2.5 h. <span class="typehead">Distribution:</span> Possibly distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 50% excreted in urine, 30% in feces. <span class="typehead">Half-Life:</span> 812 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline WBC and absolute neutrophil count must be made before initial treatment, every week for first 6 mo, then
            every 2 wk for next 6 mo, then every 4 wk, and weekly for 4 wk after the drug is discontinued. Periodically monitor blood
            glucose.
         </li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Monitor for seizure activity; seizure potential increases at the higher dose level.</li>
<li>Closely monitor for recurrence of psychotic symptoms if the drug is being discontinued.</li>
<li>Monitor cardiovascular and respiratory status, especially during the first month of therapy. Report promptly S&amp;S of CHF and
            other potential cardiac problems.
         </li>
<li>Monitor for development of tachycardia or hypotension, which may pose a serious risk for patients with compromised cardiovascular
            function.
         </li>
<li>Monitor daily temperature and report fever. Transient elevation above 38° C (100.4° F), with peak incidence during
            first 3 wk of drug therapy, may occur.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully monitor blood glucose levels if diabetic.</li>
<li>Do not engage in any hazardous activity until response to the drug is known. Drowsiness and sedation are common adverse effects.</li>
<li>Due to the risk of agranulocytosis (see Appendix F) it is important to comply with blood test regimen. Report flulike symptoms,
            fever, sore throat, lethargy, malaise, or other signs of infection.
         </li>
<li>Rise slowly to avoid orthostatic hypotension.</li>
<li>Report immediately any of the following: unexplained fatigue, especially with activity; shortness of breath, sudden weight
            gain or edema of the lower extremities.
         </li>
<li>Take drug exactly as ordered.</li>
<li>Do not use OTC drugs or alcohol without permission of physician.</li>
<li>Do not breast feed while taking clozapine.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>